Zafgen Inc (NASDAQ:ZFGN) – Investment analysts at Leerink Swann issued their Q1 2017 earnings per share estimates for Zafgen in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz anticipates that the firm will post earnings per share of ($0.49) for the quarter. Leerink Swann also issued estimates for Zafgen’s Q2 2017 earnings at ($0.53) EPS, Q3 2017 earnings at ($0.58) EPS, Q4 2017 earnings at ($0.62) EPS, FY2017 earnings at ($2.23) EPS and FY2018 earnings at ($1.48) EPS.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.12. During the same quarter last year, the business posted ($0.85) earnings per share.

Your IP Address:

Earnings History and Estimates for Zafgen (NASDAQ:ZFGN)

Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Thursday, January 12th. Cowen and Company reissued a “hold” rating on shares of Zafgen in a report on Friday, March 10th. Finally, FBR & Co reissued a “marketperform” rating on shares of Zafgen in a report on Tuesday, March 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $16.42.

Shares of Zafgen (NASDAQ:ZFGN) opened at 4.58 on Monday. The company has a 50 day moving average of $4.12 and a 200-day moving average of $3.59. Zafgen has a one year low of $2.89 and a one year high of $8.28. The firm’s market cap is $125.26 million.

Several hedge funds have recently modified their holdings of ZFGN. Royal Bank of Canada increased its stake in shares of Zafgen by 1,664.1% in the second quarter. Royal Bank of Canada now owns 44,597 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 42,069 shares during the period. Federated Investors Inc. PA increased its stake in shares of Zafgen by 27.0% in the fourth quarter. Federated Investors Inc. PA now owns 129,661 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 27,533 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Zafgen by 41.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 306,462 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 89,805 shares during the period. State Street Corp increased its stake in shares of Zafgen by 4.2% in the fourth quarter. State Street Corp now owns 352,963 shares of the biopharmaceutical company’s stock worth $1,122,000 after buying an additional 14,353 shares during the period. Finally, Spark Investment Management LLC increased its stake in shares of Zafgen by 73.5% in the third quarter. Spark Investment Management LLC now owns 347,500 shares of the biopharmaceutical company’s stock worth $1,150,000 after buying an additional 147,200 shares during the period. 50.64% of the stock is owned by institutional investors.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

5 Day Chart for NASDAQ:ZFGN

Receive News & Stock Ratings for Zafgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc and related stocks with our FREE daily email newsletter.